Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

about

Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".

P2860

Q52937933-436950FA-707E-4B27-8545-E4A1D7745945

P2860

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q48127652

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

@en

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

@nl

type

Item

label

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

@en

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

@nl

prefLabel

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

@en

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

@nl

P1476

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma

@en

P2093

Thomas C Kwee

http://www.w3.org/2001/XMLSchema#string

P2860

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

Hodgkin's lymphoma: the pathologist's viewpoint

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German

Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis.

Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.

P2888

s00259-017-3771-8

P304

1934-1936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-017-3771-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hugo J A Adams

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28707121

http://www.w3.org/2001/XMLSchema#string

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

about

P2860

P2860

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698